Active Clinical Trials

Active Clinical Trials at Huron Gastro are listed below. If you have any questions about our current research, please contact our research department at research@hurongastro.com or call (734) 714-0523  

Active Clinical Trials

 

  • In Active Ulcerative Colitis- A Randomized Controlled Trial for Determination of the Optimal Treatment Target (Treatment algorithms will feature the use of vedolizumab) (VERDICT)

  • A Phase 2, Randomized , Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate  the Efficacy, Safety, and  Pharmacokinetics  of  BFKB8488A Compared  With Placebo In  Patients  With  Nonalcoholic  Steatohepatitis (BANFF)

  • A Randomized, Placebo-controlled, Double-blind, Parallel group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis (Oral AMT-101)

  • A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)

  • A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn's Disease (LATTICE)

  • A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease (GALAXI) 

  • An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase 2/3 Studies - GA28951 (Cottonwood)

  • A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis IND#127846 (Reverse)

  • A Phase 2b/3, Multicentered, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis (M14-234 I/M)
     
  • A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in subjects with Ulcerative Colitis (AbbVie M14-533)
     
  • An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn's Disease Stratified at Higher Risk for Developing Complications (Takeda EXPLORER) 
     
  • A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcohlic Steatohepatitis (REGENERATE) 
     
  • A Phase 4 Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (AbbVie LEGACY)

Please visit  ClinicalTrials.gov  for detail information on clinical research studies listed.